Manuscript version: Author’s Accepted Manuscript
The version presented in WRAP is the author’s accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:
http://wrap.warwick.ac.uk/116359

How to cite:
Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher’s statement:
Please refer to the repository item page, publisher’s statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.
Human Vaccines & Immunotherapeutics

The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis

--Manuscript Draft--

Manuscript Number: KHVI-2018-0490R1

Full Title: The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis

Article Type: Research Paper

Manuscript Classifications: Epidemiology; HIV; Infectious Disease; Pediatrics; Tropical Medicine; Vaccinology

Abstract: There are knowledge gaps regarding evidence-based research on the burden of vaccine-preventable diseases among human immunodeficiency virus (HIV)-infected and HIV-exposed children aged <18 years in sub-Saharan Africa. It is therefore essential to determine the trend and burden of vaccine-preventable diseases. We completed a systematic review and meta-analysis to identify the incidence, prevalence and case-fatality rates (CFR) attributed to various vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. The trends in the prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed children were also determined. Nine studies on tuberculosis (TB) were pooled to give an overall incidence rate estimate of 60 (95% confidence interval [CI] 30 – 70) per 1,000 child-years. The incidence of pneumococcal infections varied between 109-1509 per 100,000 while pertussis was between 2.9 and 3.7 per 1000 child-year. Twenty-two TB prevalence studies reported an estimated prevalence of 16%. Fifteen prevalence studies on hepatitis B infection were pooled together with an estimated prevalence of 5%. The pooled prevalence for pneumococcal infections was 2% while rotavirus diarrhoea reported a prevalence of 13%. Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% while pneumococcal infections in HIV-infected and exposed children were pooled together with a resultant rate of 15%. Some of the vaccine-preventable diseases still have high incidences, prevalence and CFR among HIV-infected and HIV-exposed children. There is also a dearth of research data on the burden of several vaccine-preventable diseases among HIV-infected and exposed children and a need for more studies in this area.

Author Comments:

Order of Authors Secondary Information:

Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; burden
The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis

Olatunji O. Adetokunboh\textsuperscript{a,b,*}, Ajibola Awotiwon\textsuperscript{c}, Duduzile Nd wandwe\textsuperscript{a}, Olalekan A. Uthman\textsuperscript{a,b,d}, Charles S. Wiysonge\textsuperscript{a,b,e}

\textsuperscript{a}Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
\textsuperscript{b}Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa
\textsuperscript{c}Knowledge Translation Unit, University of Cape Town Lung Institute, Cape Town, South Africa
\textsuperscript{d}Warwick Medical School - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom
\textsuperscript{e}Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

* Correspondence: adetok_sic@yahoo.com
Abstract

There are knowledge gaps regarding evidence-based research on the burden of vaccine-preventable diseases among human immunodeficiency virus (HIV)-infected and HIV-exposed children aged <18 years in sub-Saharan Africa. It is therefore essential to determine the trend and burden of vaccine-preventable diseases. We completed a systematic review and meta-analysis to identify the incidence, prevalence and case-fatality rates (CFR) attributed to various vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. The trends in the prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed children were also determined. Nine studies on tuberculosis (TB) were pooled to give an overall incidence rate estimate of 60 (95% confidence interval [CI] 30 – 70) per 1,000 child-years. The incidence of pneumococcal infections varied between 109-1509 per 100,000 while pertussis was between 2.9 and 3.7 per 1000 child-year. Twenty-two TB prevalence studies reported an estimated prevalence of 16%. Fifteen prevalence studies on hepatitis B infection were pooled together with an estimated prevalence of 5%. The pooled prevalence for pneumococcal infections was 2% while rotavirus diarrhoea reported a prevalence of 13%. Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% while pneumococcal infections in HIV-infected and exposed children were pooled together with a resultant rate of 15%. Some of the vaccine-preventable diseases still have high incidences, prevalence and CFR among HIV-infected and HIV-exposed children. There is also a dearth of research data on the burden of several vaccine-preventable diseases among HIV-infected and exposed children and a need for more studies in this area.

Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; burden
Background

Human immunodeficiency virus (HIV) infection remains a leading public-health challenge and a principal cause of the infectious disease burden in low- and middle-income countries especially in sub-Saharan Africa. This region accounts for the bulk of HIV infection with about 36.7 million people living with the disease and an estimated 75% of the global burden. It was also estimated that approximately 2.1 million children aged under 15 years were living with HIV with the majority coming from sub-Saharan Africa and about 31% having access to antiretroviral therapy in 2014. The incidence of HIV infections among children declined in 2014 but there were still 220,000 new infections that year alone. HIV-infected children have an increased risk of developing various vaccine-preventable diseases due to their defective immune systems. This makes it crucial to focus on the vaccination of HIV-infected and exposed children. The majority of these children are also residents of low-and-middle-income countries characterised by limited access to HIV diagnosis, treatment and care.

Vaccination against various vaccine-preventable diseases has been proven to be a beneficial and cost-effective public-health measure for protecting children, adolescents and adults from these diseases, thereby reducing the morbidity and mortality attributable to them. Coverage of routine vaccinations is still low in some developing countries and not sufficient to meet the Global Vaccine Action Plan (GVAP) targets. Some African countries have low or decreasing immunisation coverage over the years with some not achieving ≥ 90% national coverage for vaccines included in their national immunisation schedule by the World Health Organization (WHO) in 2016. Sub-Saharan African countries account for about 34% of the global vaccine-preventable diseases burden, and are also responsible for the highest proportion of under-five mortality from these diseases.

Recently, most developing countries have included routine childhood vaccines such as hepatitis B; Bacillus Calmette–Guérin (BCG); diphtheria, tetanus and pertussis (DTP); *Haemophilus influenzae* type b (Hib); polio; pneumococcal conjugate; measles; rotavirus (RV), rubella and yellow fever vaccines in their national Expanded Programme on Immunisation (EPI). These vaccines also protect against diseases such as tuberculosis, poliomyelitis, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, hepatitis B infection, rubella, measles and yellow fever.
The gap in knowledge, especially in terms of evidence-based research, on the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa, warrants this study.\textsuperscript{14} This study completed a systematic review of literature and meta-analysis to identify the incidence, prevalence and mortality due to various vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa since the advent of HIV in the 1980s. This study is essential in determining the trend and current burden of vaccine-preventable disease epidemiology in sub-Saharan Africa.

**Objectives**

**Primary objectives**

1. To appraise all available published literature on the incidence and prevalence of vaccine-preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan Africa.

2. To determine the trend in the incidence and/or prevalence of vaccine-preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018.

**Secondary objective**

1. To describe the case-fatality rate ascribed to vaccine-preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan Africa.

**Results**

**Literature search and result**

Figure 1 shows the study selection process reported in line with PRISMA guidelines. We identified 3430 publications through the search of different databases. We also identified 13 additional
articles through the screening of reference lists of various related articles. We screened 188 full-text articles and selected 76 articles for inclusion in the review and 70 articles were suitable for the meta-analysis (Figure 1).

**Study characteristics**

Table 1 provides a summary of the included studies and the vaccine-preventable diseases of interest. The table shows that 45 articles reported on tuberculosis, 14 on hepatitis B virus infection, ten studies focused on pneumococcal infections, two on rotavirus gastroenteritis, three on measles and three on pertussis. The included articles consist of 41 cross-sectional studies, 31 cohort studies, four case-control studies and one time-series analysis.

South Africa had the highest number of published articles with 35 articles, Nigeria produced 10 articles, four were from Kenya, four from Ethiopia and two studies were conducted in multiple countries. The other studies were conducted in Rwanda, Tanzania, Cote d'Ivoire, Uganda, Malawi, Botswana, Zimbabwe, Zambia, Mozambique and Swaziland (Table 1). A total of 46,882 children were included in this review. HIV-infected children were included in 71 studies while two studies had both HIV-infected and HIV-exposed uninfected children, and one study with only HIV-exposed children. The included studies were conducted between 1992 and 2016.

Using the Newcastle-Ottawa Quality Scale for the quality assessment of the eligible studies, 11 articles scored eight points; 15 articles scored seven points; 27 articles scored six points; 15 articles scored five points; seven articles scored four points and two articles scored three points. The characteristics of the eligible studies are summarised in Table 1.
Figure 1: Flow diagram of the selection process
Table 1: Characteristics of the study population
**Incidence rates**

**Tuberculosis:** Nine studies\(^{15,17-20,32,35}\) on TB were pooled to give an overall incidence rate estimate of 60 (95% CI 30 – 70) per 1,000 child-years at risk for tuberculosis based on a random-effects model (\(I^2 = 99\%\); Figure 2). Subgroup analysis established change over time in incidence rates when comparing studies conducted before and after 2011. The pooled incidence rates for tuberculosis in those conducted before 2010 was 70 (95% CI 20 - 160) per 1,000 child-years\(^{32,35}\) and 40 (95% CI 20 - 50) per 1,000 child-years in studies conducted between 2011 and 2018.\(^{15,17-20,22}\) The heterogeneity of the TB incidence could not be explained by the subgroup analysis. Kouakoussui et al. reported TB incidence of 0.71 per 100 child/months before initiation of highly active antiretroviral therapy (HAART) and 0.16 per 100 child/months during HAART treatment among Ivorian HIV-infected children.\(^{60}\)

**Pneumococcal infections:** Incidence of invasive pneumococcal disease among HIV-infected children aged <1 and 1–4 years was 1022 (95% CI 923–1123) per 100,000 and 198 (95% CI 178–220) per 100,000 respectively in 2008.\(^{89}\) The incidence of pneumococcus-associated lower respiratory tract infection among HIV-exposed uninfected children was 109 (95% CI 47–214) per 100,000 and 629 (95% CI 130–1838) per 100,000 among HIV-infected children.\(^{86}\) Ásbjörnsdóttir et al. reported the incidence of pneumonia among Kenyan HIV-exposed uninfected infants to be 900 (95% CI 800–1000) per 1,000 child-years.\(^{81}\) Nunes et al. reported the incidence of invasive pneumococcal disease to be 1509 (95% CI 1350 – 1680) per 100,000 during early (HAART) and 742 (95% CI 644 – 851) during established-HAART eras for less than 18-year old South Africans.\(^{87}\)

**Pertussis:** The incidence of pertussis among Zambian HIV-exposed infants was reported to be 3.7 (95% CI 0.9–10.1) per 1000 person-months\(^{75}\) while Soofie et al. reported the incidence to be 2.9 (95% CI 1.8 – 4.5) per 1,000 child-years.\(^{78}\)

---

**Figure 2:** Forest plot of studies with data on incidence rates of tuberculosis in HIV-exposed children
Prevalence

Twenty-one TB prevalence studies were pooled together and reported estimated prevalence of 16% (95% CI 12 - 19, $I^2 = 99\%$). For studies conducted within the period 1991-2000, the prevalence was 13% (95% CI 8 - 18)$^{40,43}$; lower in 2001-2010 with an estimate of 8% (95% CI 5 - 11, $I^2 = 96\%$)$^{22,33,37,38,51}$ and recorded the highest prevalence in recent years with 15% (95% CI 8 - 22, $I^2 = 99\%$)$^{15,16,18,19,21,23,27,29,31,41,45,46,52,57}$ (Figure 3). Fourteen prevalence studies on hepatitis B (HBV) infection in HIV-infected children were pooled together with an estimate prevalence of 5% (95% CI 4 - 7, $I^2 = 90\%$). Studies conducted between 2001 and 2010 had a prevalence of 3% (95% CI 2 - 5)$^{67,68}$ and 4% (95% CI 3 – 6) between 2011 and 2018 $^{61,63,64,65-72,74}$ (Figure 4).

The pooled prevalence for pneumococcal infections was 2% (95% CI 1 – 4). There has been a reduction in prevalence from 9% (95% CI 5 - 14)$^{83}$ in 1996 to 1% (95% CI 0 – 5)$^{84}$ in 2001. Pooled prevalence for pertussis was 3% (95% CI 2 - 4)$^{14,78}$ while measles was 6% (95% CI 2 – 10)$^{75,76}$ Two rotavirus diarrhoea prevalence studies were pooled together and reported an estimated prevalence of 13% (95% CI 8 - 17, $I^2 = 0\%$)$^{79,80}$

Figure 3: Forest plot of studies with data on the prevalence of tuberculosis in HIV-infected children

Figure 4: Forest plot of studies with data on the prevalence of hepatitis B virus infection in HIV-infected and HIV-exposed children

Trend in incidence and prevalence

We analysed the trend in TB incidence with respect to publication years. The trend was non-linear with a downtrend from 2000 to 2010 (at -12.5% per year) and a reduced downward trend from 2011 to 2018 (at -1.5 per year) as shown in Figure 5. The trend in HBV prevalence was also analysed. The trend was not linear. There was evidence of a downtrend from 2000 to 2010 (at -4.7% per year) and (at -5.3% per year) from 2011 to 2018 as shown in Figure 6. The TB
prevalence trend was also non-linear. There was evidence of initial downtrend from 2000 to 2010 (at -3.2% per year) and upward trend from 2011 to 2018 (at +32.7 per year).

Figure 5: Trends in the incidence of tuberculosis in HIV-infected and exposed children with respect to publication years

Figure 6: Trends in the prevalence of hepatitis B virus infection in HIV-infected and exposed children with respect to publication years

Case-fatality rates

Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% (95% CI: 13 - 20, $I^2 = 95\%$) which translates to 17% of all TB cases dying from the disease. Subgroup analysis shows the CFR was 18% (95% CI 6 – 24)$^{47}$ in the 1991-2000 period, 6% (17 – 38, $I^2 = 95\%$) in 2001-2010 and 13% (95% CI 9 – 17, $I^2 = 96\%$)$^{15,16,18,20,23,25,30,34,39,44,46,47,50,55,56}$ in 2011 – 2018. Four studies were pooled for pneumococcal infections CF Rs in HIV-infected and exposed children with a resultant rate of 15% (95% CI 4 – 26, $I^2 = 95\%$)$^{61,84,85,90}$ One study shows that pertussis has CFRs of 13% (95% CI 2 – 38)$^78$ and for measles the CFR was 1% (95% CI 0 - 4)$^76$

Publication bias assessment

Funnel-plot analyses of studies reporting on the prevalence of TB revealed nil significant publication bias, with the P value for the Begg’s test being 0.185 while the studies assessing the prevalence of HBV infection showed significant Begg’s test with P value of 0.001 (Figure 7 and 8). Likewise, studies assessing the CFR of TB demonstrated no significant publication bias Begg’s test P = 0.385 (Figure 9).
Discussion

This study provides a comprehensive overview of the incidence rate, prevalence and case fatality rates of different vaccine-preventable diseases in HIV-infected and HIV-exposed children in sub-Saharan African countries. The review shows that TB is the most researched vaccine-preventable disease in HIV-infected children in various African countries and settings. This is not surprising because of the relationship between TB and HIV infection with respect to the high susceptibility of TB in HIV-infected individuals. Other vaccine-preventable diseases like HBV infection, pneumococcal infection, measles, rotavirus gastroenteritis, pertussis and Hib infections were also studied in several African countries. Important vaccine-preventable diseases such as poliomyelitis, diphtheria, tetanus and yellow fever had no eligible studies for inclusion revealing the dearth of incidence and prevalence studies on these diseases. The pooled incidence, prevalence and CFRs reveal there are still high burdens of several vaccine-preventable diseases in sub-Saharan Africa.

According to WHO, the global incidence of TB has been reducing at an average of 2 percent per year. TB incidence has declined in the African region by 4 percent annually since 2013. Southern African countries with the highest prevalence and incidence of HIV such as South Africa, Lesotho, Zimbabwe, Eswatini, Namibia and Zambia had remarkable reductions in TB incidence. Our study shows that TB incidence reduced over time, however, the event per child-year is still high when compared with the End TB strategy goals. The World Health Assembly adopted the resolution known as “End TB strategy goals” which is about the global strategy and targets for tuberculosis prevention, care and control after 2015. In spite of the reduction in TB incidence among children, there are still cases of high incidence in certain countries bearing in mind that many countries in African countries are classified as high-burden. A retrospective cohort study in a very high TB/HIV prevalent region in Nigeria showed a high incidence rate of 21.2/100 per year among children within six months of ART.
enrollment at a period when others were recording much lower incidence.\textsuperscript{18} TB prevalence has fluctuated over time with about 15\% of HIV-infected children having the disease at a given point in time. As of 2017, it was estimated that the global CFR was 16\% with many African countries recording more than 20\%.\textsuperscript{91} This rate is also far higher than the End TB Strategy milestone of 10\% by 2020.

The pooled HBV infection prevalence among HIV-infected children was 5\%, however, a study done in Rwanda in 2010 revealed a seroprevalence of 16\%.\textsuperscript{68} Ott et al. showed that sub-Saharan Africa had the highest HBV burden with West African countries having up to 12\% hepatitis B surface antigen prevalence among children and adolescents in the 1990s.\textsuperscript{94} There has been a reduction within the region largely due to immunisation programmes, however, there is high endemicity in some areas. A systematic review of HBV prevalence in Nigeria from studies conducted from 2000 to 2013 shows that HBV infection ranged from 0.5\% to 46.8\% with the pooled prevalence estimate for Nigeria being 13.6\%.\textsuperscript{95}

Our finding shows that the seroprevalence of rotavirus gastroenteritis among African HIV-infected children was 14\% although with a small number of included studies. The incidence and CFR of diarrhoea and pneumonia are much higher in low-income than in high-income countries and this is reflected in many African and southeast Asian countries having the highest burden of the diseases.\textsuperscript{96} The African region has the highest incidence and total death secondary to diarrhoea and pneumonia with rotavirus and \textit{Streptococcus pneumoniae} being the commonest culprits.\textsuperscript{96} Studies have shown that there is still a persistently high incidence of some vaccine-preventable diseases in HIV-infected individuals than non-exposed ones even after the introduction of highly active antiretroviral therapy.\textsuperscript{97} The incidence of pertussis is also higher in HIV-exposed and infected children, however, this decreases as the number of vaccine doses uptake increases.\textsuperscript{98}

Many African countries with high burdens of HIV are critically lagging in terms of antiretroviral treatment coverage for HIV-infected children.\textsuperscript{99} Sub-optimal ART coverage in children will lead to viral load increase, immunosuppression, etc. and a subsequent high burden of various vaccine-preventable diseases. Vaccination coverage in many African countries is still below the expected target.\textsuperscript{100} As of 2017, the average coverage of third-dose pentavalent vaccine was 80\% while the first dose of measles vaccine in the Global Alliance for Vaccines
and Immunisation (Gavi)-supported countries was 78%. The average coverage of Gavi-funded vaccines in supported countries progressed from 37% in 2016 to 41% in 2017. Use of vaccines has been established to be a beneficial healthcare intervention targeted in protecting children and adolescents from various vaccine-preventable diseases. Low uptake of vaccines by African children exposes them to more diseases than children in other regions. It has also been established that HIV-infected children are more susceptible to vaccine-preventable diseases such as TB, pneumonia, viral hepatitis etc. Vaccination is therefore essential in HIV-infected patients because of the increased risk of developing various infectious diseases due to their defective immune systems. Studies have also shown that there are poor immune responses to primary vaccination among HIV-infected children in comparison to HIV-unexposed and HIV-exposed children. The poor immune response among HIV-infected children may require booster doses for optimal immunity against vaccine-preventable diseases.

This review revealed research inequalities across the African region regarding studies on the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children. South Africa contributed about half of the included articles with Nigeria and Kenya following with fewer studies. This finding is not different from an earlier study looking at the distribution of epidemiological studies across Africa. Some of the Eastern and Southern African countries with high HIV prevalence had at least an article included in this study, however, West African countries only had publications from Nigeria and Cote d’Ivoire.

To the best of our knowledge, this is the first systematic review that addressed the need for knowing the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. Knowledge gap concerning the burden of vaccine-preventable diseases will impact negatively on the advocacy endeavours targeted at improving vaccination and vaccine-preventable diseases control efforts in Africa. Healthcare workers and policymakers need to have a good idea of the burden of different diseases to allocate resources and facilitate optimal vaccination coverage.

**Recommendations**

This review has shown that TB is one of the most important vaccine-preventable diseases in Africa with the BCG vaccine conferring protection against severe forms of the disease.
However, the same vaccine is contraindicated in immunocompromised children who ironically are susceptible to the disease. The dilemma of BCG use in HIV-exposed children warrants the call for newer and safer vaccines against TB especially in HIV-infected children. African governments and other supporting agencies should ensure that every child has access to routine childhood vaccines. Issues of under-vaccination and vaccine hesitancy should be adequately tackled to ensure better vaccine uptake and reduction in the burden of vaccine-preventable diseases.

The research capacity of African clinicians, researchers and health administrators should be built up for them to conduct basic epidemiological research such as incidence, prevalence, mortality and CFR among HIV-exposed children in various health facilities and communities. Researchers should be encouraged to disseminate their findings to their immediate communities and Departments of Health and to publish their findings in peer-reviewed journals. Established research groups such as Global Burden of Diseases Network should include the burden of vaccine-preventable diseases in HIV-exposed and non-exposed children as part of their regular or annual publications. Other African countries should emulate South Africa in increasing their research activities and outputs with respect to HIV-exposed children.

There is a need to advocate for an equitable share of healthcare budgeting and finance at every level of governance in African countries. This will help in ensuring that there is a fair share of resources for preventive and treatment services such as vaccination and antiretroviral therapy for HIV-exposed children. African countries should, as a matter of urgency, complete the introduction of newer and important vaccines such as rotavirus vaccine, Hib vaccine and pneumococcal vaccine. These should be included as part of their current national immunisation programme schedule. According to WHO, the global coverage for both pneumococcal vaccine and rotavirus vaccines were as little as 44 percent and 25 percent respectively. African countries should be supported in developing vaccine procurement budgets, procurement practices, and capacity development for vaccine planning and advocacy.

**Study limitations**

This study was limited by several factors beyond the reviewers’ control. We planned to review all the vaccine-preventable diseases associated with vaccines included in the national immunisation programme schedule in sub-Saharan Africa, however, we could not find articles that met the eligibility criteria for some of the diseases. Secondly, there was high heterogeneity
even with sub-group analysis between included studies, which implies the possibility of other contributory factors associated with the diseases. Some of the studies did not include relevant information such as antiretroviral coverage, CD4 count, viral load, vaccination status and other contributory factors. Thirdly, we could not include many studies because the diagnostic criteria for different vaccine-preventable diseases were not specified and clearly defined.

Furthermore, the presence of various limitations did not stop us from making some meaningful conclusions from this study. This review gives a clearer picture of the burden and trend of TB and able to have insights about the burden of other diseases as well despite having a small number of studies included in this review. African investigators should as a matter of priority have proper diagnostic criteria and documentation for diseases for all HIV-infected and HIV-exposed children treated at the health facilities across the region. Key parameters such as CD4 counts, vaccination status etc. should be included in future studies.

Conclusions

This systematic review and meta-analysis provide an all-inclusive analysis of the incidence rates, prevalence and CFR of various vaccine-preventable diseases. This study shows that some vaccine-preventable diseases still have high incidence, prevalence and CFRs in HIV-infected and HIV-exposed children. There was also the dearth of research activities on vaccine-preventable disease studies concerning HIV-infected and HIV-exposed uninfected children in many African countries. The findings are useful in advocating for a more equitable share of healthcare financing especially for preventive services such as vaccination of both HIV-exposed and non-exposed children to reduce the burden of vaccine-preventable diseases.

Methods and design

This systematic review was developed in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2015 statement. The review was registered with PROSPERO (International prospective register of systematic reviews) (CRD42018095341).

Inclusion criteria

Type of participants: The review included sub-Saharan African children who are HIV-infected or HIV-exposed and aged <18 years old.
**Types of outcome:**

We included studies that reported the incidence, prevalence and case-fatality rates (CFR) as outcomes in HIV-infected and HIV-exposed children.

**Primary outcomes**

Prevalence was defined as proportions of all individuals suspected of having specific vaccine-preventable diseases with confirmed laboratory diagnosis or proportions of individuals fulfilling clinical case definition for specific vaccine-preventable diseases. Incidence was defined as the number of new cases of different vaccine-preventable diseases that occur during a given period in the defined population.

We also determined the trend in the incidence and/or prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018.

**Secondary outcomes**

We included CFRs associated with vaccine-preventable diseases. Case fatality was described as mortality among confirmed or probable cases for a specific vaccine-preventable disease.

**Type of studies:** The review included cohort studies, case-control studies, cross-sectional studies and other observational studies. We planned to include studies that involved any of the following vaccine-preventable diseases:

i. Tuberculosis

ii. Poliomyelitis

iii. Hepatitis B virus infection

iv. Rotavirus gastroenteritis

v. Diphtheria

vi. Tetanus

vii. Pertussis

viii. Pneumococcal diseases

ix. Measles

x. Rubella

xi. Yellow fever

**Exclusion criteria**

- Intervention studies

- Unclear diagnostic criteria
Search strategy methods for the identification of studies

A comprehensive search strategy was developed to identify relevant studies up to August 2018, regardless of publication status or language. Scopus, Web of Science, MEDLINE via PubMed and CINAHL were searched for relevant publications. The search process was complemented by reviewing citations of all identified eligible studies. We also searched relevant World Health Organization position papers and documents on vaccines. (See Appendix for PubMed search strategy).

Selection of eligible studies

Two of the authors, (OOA and AA) screened the search results using the abstract titles. They also independently went through the full text of potential studies to assess whether they met the required inclusion criteria. Non-human studies, reviews, intervention studies, letters, commentaries and editorials were excluded. Studies not written in English, French, German, Spanish, Portuguese or Dutch were excluded. We resolved disagreements by consensus.

Data collection process

The two authors then extracted data from text, tables and figures. The data were recorded on a standardised form. We planned to contact authors of included studies in case of unclear or missing data.

The following data were extracted from selected studies:

- Study characteristics including period and design.
- Vaccine-preventable diseases patient characteristics such as age and HIV status.
- Prevalence or incidence of vaccine-preventable diseases: confirmed cases and cases meeting the clinical definition.
- Diagnostic methods: laboratory methods and clinical case definitions.
- Death attributed to vaccine-preventable diseases.

Risk of bias in individual studies

The risk of bias and quality of the included studies were assessed with the Newcastle-Ottawa Quality Scale. The criteria assessed included the following (1) selection of participants, (2) comparability, (3) exposure, and (4) outcome.
Data synthesis

OOA summarised the incidence and prevalence of various vaccine-preventable diseases. Where possible, incidence and prevalence data from each of the included studies were combined by random effects meta-analysis in accordance with the Mantel-Haenszel method.

Heterogeneity was evaluated using the Chi-squared test of homogeneity (significant for $P < 0.1$) and quantified using the I-squared statistic ($>50\%$ substantial heterogeneity). Subgroup analyses were conducted in cases with substantial heterogeneity. Subgroup analysis was conducted using the following variables: period of study (1991–2000, 2001–2010 and 2011–2018). We also used funnel plot regression to assess publication bias. STATA software version 14.0 (STATA Corporation, College Station, TX, USA) was used to do all calculations, the meta-analysis and generate forest plots.\textsuperscript{10}

Additional analyses: Trend analysis

We examined time trends in the incidence and prevalence of vaccine-preventable diseases estimates using Poisson regression models with the prevalence estimates as the outcome variable and the calendar year of the publication as the predictor. This method allows for estimation of time trends across individual calendar years to obtain average annual percentage change (AAPC), if the rate of change is at a constant rate of the previous year.\textsuperscript{11} The Poisson regression procedure fits a model of the following form:

\[
\log\left( \text{prevalence}_y \right) = b_0 + b_1 y + \log(\text{sample size})
\]

where ‘cases’ equal prevalence estimates reported per year, log is the natural log, $b0$ is the intercept, $b1$ is the trend, $y$ is the year – given as 0, 1, 2, … 18 (year 0 is 1970, year 1 is 1971, and so on to 2014), and log of ‘sample size’ was entered as the offset. The AAPC was calculated using the following formula:

\[
AAPC = \left( e^{b_1} - 1 \right) \times 100
\]

Abbreviations

BCG: Bacillus Calmette–Guérin
DTP: Diphtheria, tetanus and pertussis
EPI: Expanded Programme on Immunisation
GVAP: Global Vaccine Action Plan
Hib: *Haemophilus influenzae* type b

HIV: Human immunodeficiency virus

PCV: Pneumococcal conjugate vaccine

PRISMA: Preferred Reporting Items for Systematic Review and Meta-Analysis

RV: Rotavirus

WHO: World Health Organization

**Authors’ contributions**

OOA developed the protocol, search strategy, the data analysis and manuscript preparation. OOA and AA did the screening, study selection and data extraction. OAU and CSW guided the development of this study. All authors were involved in the results interpretation, revision and approval of the final manuscript.

**Source of funding**

OOA, DN and CSW are supported by the National Research Foundation of South Africa (Grant numbers: 106035 and 108571) and the South African Medical Research Council. OAU is supported by the National Institute of Health Research using Official Development Assistance funding. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, National Institute for Health.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**References**


Ashir GM, Rabasa AI, Gofama MM, Bukbuk D, Abubakar H, Farouk GA. Study of hepatic functions and prevalence of hepatitis B surface antigenaemia in Nigerian


64. Chotun N, Nel E, Cotton MF, Preiser W, Andersson MI. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. *Vaccine* 2015; **33**:4618–22.


von Gottberg A, Cohen C, de Gouveia L, Meiring S, Quan V, Whitelaw A, Crowther-Gibson P, Madhi SA, Whitney CG, Klugman KP. Epidemiology of invasive


StataCorp. *Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP; 2015.

**Appendix**

Search strategy - PubMed
The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis

Olatunji O. Adetokunboh\textsuperscript{a,b,*}, Ajibola Awotiwon\textsuperscript{c}, Duduzile Ndwandwe\textsuperscript{a}, Olalekan A. Uthman\textsuperscript{a,b,d}, Charles S. Wiysonge\textsuperscript{a,b,e}

\textsuperscript{a}Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
\textsuperscript{b}Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa
\textsuperscript{c}Knowledge Translation Unit, University of Cape Town Lung Institute, Cape Town, South Africa
\textsuperscript{d}Warwick Medical School - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom
\textsuperscript{e}Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

* Correspondence: adetok_sic@yahoo.com
Abstract
There are knowledge gaps regarding evidence-based research on the burden of vaccine-preventable diseases among human immunodeficiency virus (HIV)-infected and HIV-exposed children aged <18 years in sub-Saharan Africa. It is therefore essential to determine the trend and burden of vaccine-preventable diseases. We completed a systematic review and meta-analysis to identify the incidence, prevalence and case-fatality rates (CFR) attributed to various vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. The trends in the prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed children were also determined. Nine studies on tuberculosis (TB) were pooled to give an overall incidence rate estimate of 60 (95% confidence interval [CI] 30 – 70) per 1,000 child-years. The incidence of pneumococcal infections varied between 109-1509 per 100,000 while pertussis was between 2.9 and 3.7 per 1000 child-year. Twenty-two TB prevalence studies reported an estimated prevalence of 16%. Fifteen prevalence studies on hepatitis B infection were pooled together with an estimated prevalence of 5%. The pooled prevalence for pneumococcal infections was 2% while rotavirus diarrhoea reported a prevalence of 13%. Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% while pneumococcal infections in HIV-infected and exposed children were pooled together with a resultant rate of 15%. Some of the vaccine-preventable diseases still have high incidences, prevalence and CFR among HIV-infected and HIV-exposed children. There is also a dearth of research data on the burden of several vaccine-preventable diseases among HIV-infected and exposed children and a need for more studies in this area.

Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; burden
**Background**

Human immunodeficiency virus (HIV) infection remains a leading public-health challenge and a principal cause of the infectious disease burden in low- and middle-income countries especially in sub-Saharan Africa.\(^1\) This region accounts for the bulk of HIV infection with about 36.7 million people living with the disease an estimated 75% of the global burden.\(^2,3\) It was also estimated that approximately 2.1 million children aged under 15 years were living with HIV with the majority coming from sub-Saharan Africa and about 31% having access to antiretroviral therapy in 2014.\(^4\)

The incidence of HIV infections among children declined in 2014 but there were still 220,000 new infections that year alone.\(^5\) HIV-infected children have an increased risk of developing various vaccine-preventable diseases due to their defective immune systems.\(^5\) This makes it crucial to focus on the vaccination of HIV-infected and exposed children. The majority of these children are also residents of low-and-middle-income countries characterised by limited access to HIV diagnosis, treatment and care.\(^2\)

Vaccination against various vaccine-preventable diseases has been proven to be a beneficial and cost-effective public-health measure for protecting children, adolescents and adults from these diseases, thereby reducing the morbidity and mortality attributable to them.\(^5,7\) Coverage of routine vaccinations is still low in some developing countries and not sufficient to meet the Global Vaccine Action Plan (GVAP) targets.\(^8–10\) Some African countries have low or decreasing immunisation coverage over the years with some not achieving ≥ 90% national coverage for vaccines included in their national immunisation schedule by the World Health Organization (WHO) in 2016.\(^11\) Sub-Saharan African countries account for about 34% of the global vaccine-preventable diseases burden, and are also responsible for the highest proportion of under-five mortality from these diseases.\(^12\)

Recently, most developing countries have included routine childhood vaccines such as hepatitis B; Bacillus Calmette–Guérin (BCG); diphtheria, tetanus and pertussis (DTP); *Haemophilus influenzae* type b (Hib); polio; pneumococcal conjugate; measles; rotavirus (RV), rubella and yellow fever vaccines in their national Expanded Programme on Immunisation (EPI).\(^13\) These vaccines also protect against diseases such as tuberculosis, poliomyelitis, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, hepatitis B infection, rubella, measles and yellow fever.
The gap in knowledge, especially in terms of evidence-based research, on the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa, warrants this study. This study completed a systematic review of literature and meta-analysis to identify the incidence, prevalence and mortality due to various vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa since the advent of HIV in the 1980s. This study is essential in determining the trend and current burden of vaccine-preventable disease epidemiology in sub-Saharan Africa.

Objectives

Primary objectives

1. To appraise all available published literature on the incidence and prevalence of vaccine-preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan Africa.

2. To determine the trend in the incidence and/or prevalence of vaccine-preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018.

Secondary objective

1. To describe the case-fatality rate ascribed to vaccine-preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan Africa.

Results

Literature search and result

Figure 1 shows the study selection process reported in line with PRISMA guidelines. We identified 3430 publications through the search of different databases. We also identified 13 additional
articles through the screening of reference lists of various related articles. We screened 188 full-
text articles and selected 76 articles for inclusion in the review and 70 articles were suitable for
the meta-analysis (Figure 1).

Study characteristics
Table 1 provides a summary of the included studies and the vaccine-preventable diseases of
interest. The table shows that 45 articles reported on tuberculosis, 14 on hepatitis B virus infection,
ten studies focused on pneumococcal infections, two on rotavirus gastroenteritis, three on measles
and three on pertussis. The included articles consist of 41 cross-sectional studies, 31 cohort studies,
four case-control studies and one time-series analysis.

South Africa had the highest number of published articles with 35 articles, Nigeria produced 10
articles, four were from Kenya, four from Ethiopia and two studies were conducted in multiple
countries. The other studies were conducted in Rwanda, Tanzania, Cote d’Ivoire, Uganda, Malawi,
Botswana, Zimbabwe, Zambia, Mozambique and Swaziland (Table 1). A total of 46,882 children
were included in this review. HIV-infected children were included in 71 studies while two studies
had both HIV-infected and HIV-exposed uninfected children, and one study with only HIV-
exposed children. The included studies were conducted between 1992 and 2016.

Using the Newcastle-Ottawa Quality Scale for the quality assessment of the eligible studies, 11
articles scored eight points; 15 articles scored seven points; 27 articles scored six points; 15 articles
scored five points; seven articles scored four points and two articles scored three points. The
characteristics of the eligible studies are summarised in Table 1.
Figure 1: Flow diagram of the selection process

- Records identified through database searching (n = 3430)
- Additional records identified through other sources (n = 13)
- Excluded duplicated records (n = 2101)
- Records after duplicates removed (n = 1342)

- Full-text articles assessed for eligibility
  - Studies included in qualitative synthesis (n = 76)
  - Full-text articles excluded, with reasons (n = 1154)
    - Abstracts
    - Did not report outcome of choice
    - Diagnostic criteria not well defined
    - Person-year not stated for the analysis of incidence
    - Reviews
  - (n = 1342)

- Full-text articles assessed for eligibility
  - Studies included in qualitative synthesis (n = 76)
  - Full-text articles excluded, with reasons (n = 112)
    - Did not report outcome of choice
    - Diagnostic criteria not well defined
    - Person-year not stated for the analysis of incidence
    - Reviews

- Studies included in quantitative synthesis (meta-analysis) (n = 70)
### Table 1: Characteristics of the study population

<table>
<thead>
<tr>
<th>First author and year</th>
<th>Study period</th>
<th>Study design</th>
<th>Country</th>
<th>Sample size</th>
<th>VPD</th>
<th>Outcomes</th>
<th>HIV status</th>
<th>Quality scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abuogi 2013</td>
<td>2009–2010</td>
<td>Cohort</td>
<td>Kenya</td>
<td>689</td>
<td></td>
<td>Tuberculosis</td>
<td>C, L, R</td>
<td>III 2</td>
</tr>
<tr>
<td>Alema 2016</td>
<td>2009–2014</td>
<td>Cohort</td>
<td>Ethiopia</td>
<td>645</td>
<td></td>
<td>Tuberculosis</td>
<td>L</td>
<td>III 6</td>
</tr>
<tr>
<td>Angililaje 2016</td>
<td>2010–2013</td>
<td>Cohort</td>
<td>Nigeria</td>
<td>268</td>
<td></td>
<td>Tuberculosis</td>
<td>P</td>
<td>III 8</td>
</tr>
<tr>
<td>Auld 2014</td>
<td>2004–2008</td>
<td>Cohort</td>
<td>Cote-d'Ivoire</td>
<td>3110</td>
<td></td>
<td>Tuberculosis</td>
<td>L, R</td>
<td>III 8</td>
</tr>
<tr>
<td>Bakesa 2011</td>
<td>2003–2006</td>
<td>Cohort</td>
<td>Uganda</td>
<td>1806</td>
<td></td>
<td>Tuberculosis</td>
<td>L, C</td>
<td>III 8</td>
</tr>
<tr>
<td>Bonnet 2018</td>
<td>2012–2014</td>
<td>Cohort</td>
<td>Uganda</td>
<td>113</td>
<td></td>
<td>Tuberculosis</td>
<td>C</td>
<td>III 2</td>
</tr>
<tr>
<td>Buck 2013</td>
<td>2010</td>
<td>Cohort</td>
<td>Malawi</td>
<td>4824</td>
<td></td>
<td>Tuberculosis</td>
<td>C, R</td>
<td>III 8</td>
</tr>
<tr>
<td>Cariucci 2012</td>
<td>2013–2014</td>
<td>Cohort</td>
<td>Multiple</td>
<td>386</td>
<td></td>
<td>Tuberculosis</td>
<td>C</td>
<td>III 8</td>
</tr>
<tr>
<td>Chaya 2016</td>
<td>2006–2011</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>43</td>
<td></td>
<td>Tuberculosis</td>
<td>L</td>
<td>III 6</td>
</tr>
<tr>
<td>Cruz 2015</td>
<td>NR</td>
<td>Cohort</td>
<td>Botswana</td>
<td>100</td>
<td></td>
<td>Tuberculosis</td>
<td>P</td>
<td>III 6</td>
</tr>
<tr>
<td>De Maeyer 2011</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>58</td>
<td></td>
<td>Tuberculosis</td>
<td>P</td>
<td>III 2</td>
</tr>
<tr>
<td>Ebonyi 2016b</td>
<td>2005–2013</td>
<td>Cohort</td>
<td>Nigeria</td>
<td>876</td>
<td></td>
<td>Tuberculosis</td>
<td>P</td>
<td>III 2</td>
</tr>
<tr>
<td>Ekeng 2005</td>
<td>2000–2003</td>
<td>Cohort</td>
<td>Cote-d'Ivoire</td>
<td>282</td>
<td></td>
<td>Tuberculosis</td>
<td>L</td>
<td>III 8</td>
</tr>
<tr>
<td>Hall 2017</td>
<td>2005–2008</td>
<td>Cohort</td>
<td>South Africa</td>
<td>224</td>
<td></td>
<td>Tuberculosis</td>
<td>C</td>
<td>III 8</td>
</tr>
<tr>
<td>Hesseling 2009a</td>
<td>2001–2006</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>2221</td>
<td></td>
<td>Tuberculosis</td>
<td>C</td>
<td>III 6</td>
</tr>
<tr>
<td>Hesseling 2009b</td>
<td>2004–2006</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>2221</td>
<td></td>
<td>Tuberculosis</td>
<td>L, R</td>
<td>III 2</td>
</tr>
<tr>
<td>Hick 2014</td>
<td>2009–2010</td>
<td>Cohort</td>
<td>South Africa</td>
<td>64</td>
<td></td>
<td>Tuberculosis</td>
<td>C</td>
<td>III 6</td>
</tr>
<tr>
<td>Meyers 2000</td>
<td>1996</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>144</td>
<td></td>
<td>Tuberculosis</td>
<td>P</td>
<td>III 5</td>
</tr>
<tr>
<td>Reference</td>
<td>Year</td>
<td>Design</td>
<td>Country</td>
<td>Age</td>
<td>Disease</td>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>------</td>
<td>----------</td>
<td>---------------------</td>
<td>-----</td>
<td>------------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obiagwu 2013</td>
<td>2013</td>
<td>Cohort</td>
<td>Nigeria</td>
<td>2</td>
<td>Tuberculosis</td>
<td>P, M, F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cross-sectional</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wirth 2015</td>
<td>2015</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telatela 2007</td>
<td>2007</td>
<td>Cohort</td>
<td>Ethiopia</td>
<td>1</td>
<td>Tuberculosis</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sadoh 2011</td>
<td>2011</td>
<td>Cohort</td>
<td>Cyprus</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muro 2013</td>
<td>2013</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jooste 2016</td>
<td>2016</td>
<td>Cohort</td>
<td>Tanzania</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ikpeme 2013</td>
<td>2013</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dziuban 2013</td>
<td>2013</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ashir 2009</td>
<td>2009</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seetars 2009</td>
<td>2009</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wulfe 2009</td>
<td>2009</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newles 2011</td>
<td>2011</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sadoh 2011</td>
<td>2011</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telatela 2007</td>
<td>2007</td>
<td>Cohort</td>
<td>South Africa</td>
<td>1</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Design</td>
<td>Country</td>
<td>N</td>
<td>Disease</td>
<td>Score</td>
<td>Score</td>
<td>Score</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------</td>
<td>-------------</td>
<td>---------------</td>
<td>-----</td>
<td>----------------------------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>Gill 2016**</td>
<td>2015</td>
<td>Cohort</td>
<td>Zambia</td>
<td>347</td>
<td>Pertussis</td>
<td>1</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Soofie 2016**</td>
<td>2015</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>599</td>
<td>Pertussis</td>
<td>C.I.P</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Johnson 2000**</td>
<td>1996-1997</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>31</td>
<td>Rotavirus gastroenteritis</td>
<td>R</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Mayo 2014**</td>
<td>2010-2011</td>
<td>Case-control</td>
<td>Tanzania</td>
<td>26</td>
<td>Rotavirus gastroenteritis</td>
<td>R</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Asbjørnsdóttir 2013**</td>
<td>1999-2002</td>
<td>Cohort</td>
<td>Kenya</td>
<td>388</td>
<td>Pneumococcal infection</td>
<td>C.I</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Zar 2001**</td>
<td>1998</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>151</td>
<td>Pneumococcal infection</td>
<td>R</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Jones 1998**</td>
<td>1996</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>25</td>
<td>Pneumococcal infection</td>
<td>C</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Roca 2010**</td>
<td>2004-2006</td>
<td>Cross-sectional</td>
<td>Mozambique</td>
<td>54</td>
<td>Pneumococcal infection</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Cohen 2016**</td>
<td>2009-2013</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>211</td>
<td>Pneumococcal infection</td>
<td>I</td>
<td>I</td>
<td>4</td>
</tr>
<tr>
<td>Blunet 2011**</td>
<td>2003-2008</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>918</td>
<td>Pneumococcal infection</td>
<td>I</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>von Mollendorf 2017**</td>
<td>2009-2013</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>485</td>
<td>Pneumococcal infection</td>
<td>C.I</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>von Gottberg 2013**</td>
<td>2003-2005</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>1740</td>
<td>Pneumococcal infection</td>
<td>I</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Nyasulu 2011**</td>
<td>2003-2005</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>1524</td>
<td>Pneumococcal infection</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
</tbody>
</table>

NR—Not recorded; C—Case-fatality rate; I—Incidence; P—Prevalence; Hib—Haemophilus influenzae type b; HI—HIV infected; HE—HIV exposed; HEU—HIV exposed uninfected; VPD—Vaccine-preventable diseases.
Incidence rates

Tuberculosis: Nine studies on TB were pooled to give an overall incidence rate estimate of 60 (95% CI 30 – 70) per 1,000 child-years at risk for tuberculosis based on a random-effects model ($I^2 = 99\%$; Figure 2). Subgroup analysis established change over time in incidence rates when comparing studies conducted before and after 2011. The pooled incidence rates for tuberculosis in those conducted before 2010 was 70 (95% CI 20 - 160) per 1,000 child-years and 40 (95% CI 20 - 50) per 1,000 child-years in studies conducted between 2011 and 2018. The heterogeneity of the TB incidence could not be explained by the subgroup analysis. Kouakoussui et al. reported TB incidence of 0.71 per 100 child/months before initiation of highly active antiretroviral therapy (HAART) and 0.16 per 100 child/months during HAART treatment among Ivorian HIV-infected children.

Pneumococcal infections: Incidence of invasive pneumococcal disease among HIV-infected children aged <1 and 1–4 years was 1022 (95% CI 923–1123) per 100,000 and 198 (95% CI 178–220) per 100,000 respectively in 2008. The incidence of pneumococcus-associated lower respiratory tract infection among HIV-exposed uninfected children was 109 (95% CI 47–214) per 100,000 and 629 (95% CI 130–1838) per 100,000 among HIV-infected children. Ásbjörnsdóttir et al. reported the incidence of pneumonia among Kenyan HIV-exposed uninfected infants to be 900 (95% CI 800–1000) per 1,000 child-years. Nunes et al. reported the incidence of invasive pneumococcal disease to be 1509 (95% CI 1350 – 1680) per 100,000 during early (HAART) and 742 (95% CI 644 – 851) during established-HAART eras for less than 18-year old South Africans.

Pertussis: The incidence of pertussis among Zambian HIV-exposed infants was reported to be 3.7 (95% CI 0.9–10.1) per 1000 person-months while Soofie et al. reported the incidence to be 2.9 (95% CI 1.8 – 4.5) per 1,000 child-years.
Figure 2: Forest plot of studies with data on incidence rates of tuberculosis in HIV-exposed children

**Prevalence**

Twenty-one TB prevalence studies were pooled together and reported estimated prevalence of 16% (95% CI 12 - 19, $I^2 = 99\%$). For studies conducted within the period 1991-2000, the prevalence was 13% (95% CI 8 - 18)\(^{40,43}\); lower in 2001-2010 with an estimate of 8% (95% CI 5 - 11, $I^2 = 96\%$)\(^{22,33,37,38,51}\) and recorded the highest prevalence in recent years with 15% (95% CI 8 - 22, $I^2 = 99\%$)\(^{15,16,18,19,21,23,27,29,31,41,45,46,52,57}\) (Figure 3). Fourteen prevalence studies on hepatitis B (HBV) infection in HIV-infected children were pooled together with an estimate prevalence of 5% (95% CI 4 - 7, $I^2 = 90\%$). Studies conducted between 2001 and 2010 had a prevalence of 3% (95% CI 2 - 5)\(^{67,68}\) and 4% (95% CI 3 – 6) between 2011 and 2018\(^{61,63,64,65,72,74}\) (Figure 4).

The pooled prevalence for pneumococcal infections was 2% (95% CI 1 – 4). There has been a reduction in prevalence from 9% (95% CI 5 - 14)\(^{83}\) in 1996 to 1% (95% CI 0 – 5)\(^{84}\) in 2001. Pooled prevalence for pertussis was 3% (95% CI 2 - 4)\(^{14,78}\) while measles was 6% (95% CI 2 – 10)\(^{75,76}\). Two rotavirus diarrhoea prevalence studies were pooled together and reported an estimated prevalence of 13% (95% CI 8 - 17, $I^2 = 0\%$)\(^{79,80}\).
Figure 3: Forest plot of studies with data on the prevalence of tuberculosis in HIV-infected children
Figure 4: Forest plot of studies with data on the prevalence of hepatitis B virus infection in HIV-infected and HIV-exposed children

Trend in incidence and prevalence

We analysed the trend in TB incidence with respect to publication years. The trend was non-linear with a downtrend from 2000 to 2010 (at -12.5% per year) and a reduced downward trend from 2011 to 2018 (at -1.5% per year) as shown in Figure 5. The trend in HBV prevalence was also analysed. The trend was not linear. There was evidence of a downtrend from 2000 to 2010 (at -4.7% per year) and (at -5.3% per year) from 2011 to 2018 as shown in Figure 6. The TB prevalence trend was also non-linear. There was evidence of initial downtrend from 2000 to 2010 (at -3.2% per year) and upward trend from 2011 to 2018 (at +32.7 per year).
Figure 5: Trends in the incidence of tuberculosis in HIV-infected and exposed children with respect to publication years
Figure 6: Trends in the prevalence of hepatitis B virus infection in HIV-infected and exposed children with respect to publication years

Case-fatality rates

Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% (95% CI: 13 - 20, $I^2 = 95\%$) which translates to 17% of all TB cases dying from the disease. Subgroup analysis shows the CFR was 18% (95% CI 6 – 24)\(^7\) in the 1991-2000 period, 6% (17 – 38, $I^2 = 95\%$)\(^47\) in 2001-2010 and 13% (95% CI 9 – 17, $I^2 = 96\%$)\(^15,16,18,20,23,25,30,34,39,44,46,47,50,55,56\) in 2011 – 2018. Four studies were pooled for pneumococcal infections CFRs in HIV-infected and exposed children with a resultant rate of 15% (95% CI 4 – 26, $I^2 = 95\%)\(^{81,84,85,90}\) One study shows that pertussis has CFRs of 13% (95% CI 2 – 38)\(^78\) and for measles the CFR was 1% (95% CI 0 - 4).\(^76\)
**Publication bias assessment**

Funnel-plot analyses of studies reporting on the prevalence of TB revealed nil significant publication bias, with the $P$ value for the Begg’s test being 0.185 while the studies assessing the prevalence of HBV infection showed significant Begg’s test with $P$ value of 0.001 (Figure 7 and 8). Likewise, studies assessing the CFR of TB demonstrated no significant publication bias Begg’s test $P = 0.385$ (Figure 9).

![Funnel plot with pseudo 95% confidence limits](image)

Figure 7: Funnel plot of studies reporting on the prevalence of tuberculosis in HIV-infected children
Figure 8: Funnel plot of studies reporting on the prevalence of hepatitis B virus infection in HIV-infected children

Figure 9: Funnel plot of studies reporting on the case-fatality rate of tuberculosis in HIV-infected children
Discussion

This study provides a comprehensive overview of the incidence rate, prevalence and case
fatality rates of different vaccine-preventable diseases in HIV-infected and HIV-exposed
children in sub-Saharan African countries. The review shows that TB is the most researched
vaccine-preventable disease in HIV-infected children in various African countries and settings.
This is not surprising because of the relationship between TB and HIV infection with respect
to the high susceptibility of TB in HIV-infected individuals.\textsuperscript{91,92} Other vaccine-preventable
diseases like HBV infection, pneumococcal infection, measles, rotavirus gastroenteritis,
pertussis and Hib infections were also studied in several African countries. Important vaccine-
preventable diseases such as poliomyelitis, diphtheria, tetanus and yellow fever had no eligible
studies for inclusion revealing the dearth of incidence and prevalence studies on these diseases.
The pooled incidence, prevalence and CFRs reveal there are still high burdens of several
vaccine-preventable diseases in sub-Saharan Africa.

According to WHO, the global incidence of TB has been reducing at an average of 2 percent
per year.\textsuperscript{91} TB incidence has declined in the African region by 4 percent annually since 2013.\textsuperscript{91}
Southern African countries with the highest prevalence and incidence of HIV such as South
Africa, Lesotho, Zimbabwe, Eswatini, Namibia and Zambia had remarkable reductions in TB
incidence.\textsuperscript{91} Our study shows that TB incidence reduced over time, however, the event per
child-year is still high when compared with the End TB strategy goals.\textsuperscript{93} The World Health
Assembly adopted the resolution known as “End TB strategy goals” which is about the global
strategy and targets for tuberculosis prevention, care and control after 2015.\textsuperscript{93} In spite of the
reduction in TB incidence among children, there are still cases of high incidence in certain
countries bearing in mind that many countries in African countries are classified as high-
burden.\textsuperscript{96} A retrospective cohort study in a very high TB/HIV prevalent region in Nigeria
showed a high incidence rate of 21.2/100 per year among children within six months of ART
enrollment at a period when others were recording much lower incidence.\textsuperscript{18} TB prevalence has
fluctuated over time with about 15% of HIV-infected children having the disease at a given
point in time. As of 2017, it was estimated that the global CFR was 16% with many African
countries recording more than 20%.\textsuperscript{91} This rate is also far higher than the End TB Strategy
milestone of 10% by 2020.

The pooled HBV infection prevalence among HIV-infected children was 5%, however, a study
done in Rwanda in 2010 revealed a seroprevalence of 16%.\textsuperscript{68} Ott et al. showed that sub-Saharan
Africa had the highest HBV burden with West African countries having up to 12% hepatitis B surface antigen prevalence among children and adolescents in the 1990s. There has been a reduction within the region largely due to immunisation programmes, however, there is high endemicity in some areas. A systematic review of HBV prevalence in Nigeria from studies conducted from 2000 to 2013 shows that HBV infection ranged from 0.5% to 46.8% with the pooled prevalence estimate for Nigeria being 13.6%.

Our finding shows that the seroprevalence of rotavirus gastroenteritis among African HIV-infected children was 14% although with a small number of included studies. The incidence and CFR of diarrhoea and pneumonia are much higher in low-income than in high-income countries and this is reflected in many African and southeast Asian countries having the highest burden of the diseases. The African region has the highest incidence and total death secondary to diarrhoea and pneumonia with rotavirus and *Streptococcus pneumoniae* being the commonest culprits. Studies have shown that there is still a persistently high incidence of some vaccine-preventable diseases in HIV-infected individuals than non-exposed ones even after the introduction of highly active antiretroviral therapy. The incidence of pertussis is also higher in HIV-exposed and infected children, however, this decreases as the number of vaccine doses uptake increases.

Many African countries with high burdens of HIV are critically lagging in terms of antiretroviral treatment coverage for HIV-infected children. Sub-optimal ART coverage in children will lead to viral load increase, immunosuppression, etc. and a subsequent high burden of various vaccine-preventable diseases. Vaccination coverage in many African countries is still below the expected target. As of 2017, the average coverage of third-dose pentavalent vaccine was 80% while the first dose of measles vaccine in the Global Alliance for Vaccines and Immunisation (Gavi)-supported countries was 78%. The average coverage of Gavi-funded vaccines in supported countries progressed from 37% in 2016 to 41% in 2017.

Low uptake of vaccines by African children exposes them to more diseases than children in other regions. Use of vaccines has been established to be a beneficial healthcare intervention targeted in protecting children and adolescents from various vaccine-preventable diseases. Low uptake of vaccines by African children exposes them to more diseases than children in other regions. It has also been established that HIV-infected children are more susceptible to vaccine-preventable diseases such as TB, pneumonia, viral hepatitis etc.
therefore essential in HIV-infected patients because of the increased risk of developing various infectious diseases due to their defective immune systems. Studies have also shown that there are poor immune responses to primary vaccination among HIV-infected children in comparison to HIV-unexposed and HIV-exposed children. The poor immune response among HIV-infected children may require booster doses for optimal immunity against vaccine-preventable diseases.103,104

This review revealed research inequalities across the African region regarding studies on the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children. South Africa contributed about half of the included articles with Nigeria and Kenya following with fewer studies. This finding is not different from an earlier study looking at the distribution of epidemiological studies across Africa.105 Some of the Eastern and Southern African countries with high HIV prevalence had at least an article included in this study, however, West African countries only had publications from Nigeria and Cote d’Ivoire.

To the best of our knowledge, this is the first systematic review that addressed the need for knowing the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. Knowledge gap concerning the burden of vaccine-preventable diseases will impact negatively on the advocacy endeavours targeted at improving vaccination and vaccine-preventable diseases control efforts in Africa. Healthcare workers and policymakers need to have a good idea of the burden of different diseases to allocate resources and facilitate optimal vaccination coverage.

Recommendations
This review has shown that TB is one of the most important vaccine-preventable diseases in Africa with the BCG vaccine conferring protection against severe forms of the disease. However, the same vaccine is contraindicated in immunocompromised children who ironically are susceptible to the disease.13 The dilemma of BCG use in HIV-exposed children warrants the call for newer and safer vaccines against TB especially in HIV-infected children. African governments and other supporting agencies should ensure that every child has access to routine childhood vaccines. Issues of under-vaccination and vaccine hesitancy should be adequately tackled to ensure better vaccine uptake and reduction in the burden of vaccine-preventable diseases.
The research capacity of African clinicians, researchers and health administrators should be built up for them to conduct basic epidemiological research such as incidence, prevalence, mortality and CFR among HIV-exposed children in various health facilities and communities. Researchers should be encouraged to disseminate their findings to their immediate communities and Departments of Health and to publish their findings in peer-reviewed journals. Established research groups such as Global Burden of Diseases Network should include the burden of vaccine-preventable diseases in HIV-exposed and non-exposed children as part of their regular or annual publications. Other African countries should emulate South Africa in increasing their research activities and outputs with respect to HIV-exposed children.

There is a need to advocate for an equitable share of healthcare budgeting and finance at every level of governance in African countries. This will help in ensuring that there is a fair share of resources for preventive and treatment services such as vaccination and antiretroviral therapy for HIV-exposed children. African countries should, as a matter of urgency, complete the introduction of newer and important vaccines such as rotavirus vaccine, Hib vaccine and pneumococcal vaccine. These should be included as part of their current national immunisation programme schedule. According to WHO, the global coverage for both pneumococcal vaccine and rotavirus vaccines were as little as 44 percent and 25 percent respectively. African countries should be supported in developing vaccine procurement budgets, procurement practices, and capacity development for vaccine planning and advocacy.

**Study limitations**

This study was limited by several factors beyond the reviewers’ control. We planned to review all the vaccine-preventable diseases associated with vaccines included in the national immunisation programme schedule in sub-Saharan Africa, however, we could not find articles that met the eligibility criteria for some of the diseases. Secondly, there was high heterogeneity even with sub-group analysis between included studies, which implies the possibility of other contributory factors associated with the diseases. Some of the studies did not include relevant information such as antiretroviral coverage, CD4 count, viral load, vaccination status and other contributory factors. Thirdly, we could not include many studies because the diagnostic criteria for different vaccine-preventable diseases were not specified and clearly defined.

Furthermore, the presence of various limitations did not stop us from making some meaningful conclusions from this study. This review gives a clearer picture of the burden and trend of TB.
and able to have insights about the burden of other diseases as well despite having a small number of studies included in this review. African investigators should as a matter of priority have proper diagnostic criteria and documentation for diseases for all HIV-infected and HIV-exposed children treated at the health facilities across the region. Key parameters such as CD4 counts, vaccination status etc. should be included in future studies.

Conclusions
This systematic review and meta-analysis provide an all-inclusive analysis of the incidence rates, prevalence and CFR of various vaccine-preventable diseases. This study shows that some vaccine-preventable diseases still have high incidence, prevalence and CFRs in HIV-infected and HIV-exposed children. There was also the dearth of research activities on vaccine-preventable disease studies concerning with respect to HIV-infected and HIV-exposed uninfected children in many African countries. The findings are useful in advocating for a more equitable share of healthcare financing especially for preventive services such as vaccination of both HIV-exposed and non-exposed children in order to reduce the burden of vaccine-preventable diseases.

Methods and design
This systematic review was developed in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2015 statement. The review was registered with PROSPERO (International prospective register of systematic reviews) (CRD42018095341).

Inclusion criteria
Type of participants: The review included sub-Saharan African children who are HIV-infected or HIV-exposed and aged <18 years old.

Types of outcome:
We included studies that reported the incidence, prevalence and case-fatality rates (CFR) as outcomes in HIV-infected and HIV-exposed children.

Primary outcomes
Prevalence was defined as proportions of all individuals suspected of having specific vaccine-preventable diseases with confirmed laboratory diagnosis or proportions of individuals fulfilling clinical case definition for specific vaccine-preventable diseases. Incidence was
defined as the number of new cases of different vaccine-preventable diseases that occur during a given period in the defined population.

We also determined the trend in the incidence and/or prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018.

**Secondary outcomes**
We included CFRs associated with vaccine-preventable diseases. Case fatality was described as mortality among confirmed or probable cases for a specific vaccine-preventable disease.

**Type of studies:** The review included cohort studies, case-control studies, cross-sectional studies and other observational studies. We planned to include studies that involved any of the following vaccine-preventable diseases:

i. Tuberculosis
ii. Poliomyelitis
iii. Hepatitis B virus infection
iv. Rotavirus gastroenteritis
v. Diphtheria
vi. Tetanus
vii. Pertussis
viii. Pneumococcal diseases
ix. Measles
x. Rubella
xi. Yellow fever

**Exclusion criteria**
- Intervention studies
- Unclear diagnostic criteria

**Search strategy methods for the identification of studies**
A comprehensive search strategy was developed to identify relevant studies up to August 2018, regardless of publication status or language. Scopus, Web of Science, MEDLINE via PubMed and CINAHL were searched for relevant publications. The search process was complemented by reviewing citations of all identified eligible studies. We also searched relevant World Health
Organization position papers and documents on vaccines. (See Appendix for PubMed search strategy).

Selection of eligible studies
Two of the authors, (OOA and AA) screened the search results using the abstract titles. They also independently went through the full text of potential studies to assess whether they met the required inclusion criteria. Non-human studies, reviews, intervention studies, letters, commentaries and editorials were excluded. Studies not written in English, French, German, Spanish, Portuguese or Dutch were excluded. We resolved disagreements by consensus.

Data collection process
The two authors then extracted data from text, tables and figures. The data were recorded on a standardised form. We planned to contact authors of included studies in case of unclear or missing data.

The following data were extracted from selected studies:

- Study characteristics including period and design.
- Vaccine-preventable diseases patient characteristics such as age and HIV status.
- Prevalence or incidence of vaccine-preventable diseases: confirmed cases and cases meeting the clinical definition.
- Diagnostic methods: laboratory methods and clinical case definitions.
- Death attributed to vaccine-preventable diseases.

Risk of bias in individual studies
The risk of bias and quality of the included studies were assessed with the Newcastle-Ottawa Quality Scale. The criteria assessed included the following (1) selection of participants, (2) comparability, (3) exposure, and (4) outcome.

Data synthesis
OOA summarised the incidence and prevalence of various vaccine-preventable diseases. Where possible, incidence and prevalence data from each of the included studies were combined by random effects meta-analysis in accordance with the Mantel-Haenszel method.

Heterogeneity was evaluated using the Chi-squared test of homogeneity (significant for $P < 0.1$) and quantified using the I-squared statistic (>50% substantial heterogeneity). Subgroup analyses were conducted in cases with substantial heterogeneity.
conducted using the following variables: period of study (1991-2000, 2001-2010 and 2011-2018). We also used funnel plot regression to assess publication bias. STATA software version 14.0 (STATA Corporation, College Station, TX, USA) was used to do all calculations, the meta-analysis and generate forest plots.  

Additional analyses: Trend analysis
We examined time trends in the incidence and prevalence of vaccine-preventable diseases estimates using Poisson regression models with the prevalence estimates as the outcome variable and the calendar year of the publication as the predictor. This method allows for estimation of time trends across individual calendar years to obtain average annual percentage change (AAPC), assuming that the rate of change is at a constant rate of the previous year.  

The Poisson regression procedure fits a model of the following form:

$$\log(\text{prevalence}) = b_0 + b_1 y + \log(\text{sample size})$$  

(1)

where ‘cases’ equal prevalence estimates reported per year, log is the natural log, $b_0$ is the intercept, $b_1$ is the trend, $y$ is the year – given as 0, 1, 2, … 18 (year 0 is 1970, year 1 is 1971, and so on to 2014), and log of ‘sample size’ was entered as the offset. The AAPC was calculated using the following formula:

$$AAPC = (e^{b_1} - 1) \times 100$$  

(2)

Abbreviations
BCG: Bacillus Calmette–Guérin
DTP: Diphtheria, tetanus and pertussis
EPI: Expanded Programme on Immunisation
GVAP: Global Vaccine Action Plan
Hib: *Haemophilus influenzae* type b
HIV: Human immunodeficiency virus
PCV: Pneumococcal conjugate vaccine
PRISMA: Preferred Reporting Items for Systematic Review and Meta-Analysis
RV: Rotavirus
WHO: World Health Organization
Authors’ contributions

OOA developed the protocol, search strategy, the data analysis and manuscript preparation. OOA and AA did the screening, study selection and data extraction. OAU and CSW guided the development of this study. All authors were involved in the results interpretation, revision and approval of the final manuscript.

Source of funding

OOA, DN and CSW are supported by the National Research Foundation of South Africa (Grant numbers: 106035 and 108571) and the South African Medical Research Council. OAU is supported by the National Institute of Health Research using Official Development Assistance funding. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, National Institute for Health.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

References


64. Chotun N, Nel E, Cotton MF, Preiser W, Andersson MI. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. *Vaccine* 2015; 33:4618–22.


73. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the


103. Mutsaerts EAML, Nunes MC, van Rijswijk MN, Klipstein-Grobusch K, Grobbee DE, Madhi SA. Safety and Immunogenicity of Measles Vaccination in HIV-Infected and


### Search strategy - PubMed

<table>
<thead>
<tr>
<th>Search</th>
<th>Add to builder</th>
<th>Query</th>
<th>Items found</th>
</tr>
</thead>
<tbody>
<tr>
<td>46</td>
<td>Add</td>
<td>Search (((#1) AND #2) AND #3) AND #4) AND #5</td>
<td>Sort by: Best Match</td>
</tr>
<tr>
<td>44</td>
<td>Add</td>
<td>Search (newborn* OR bab* OR infant* OR child* OR adolescent OR teen*)</td>
<td>Sort by: Best Match</td>
</tr>
<tr>
<td>42</td>
<td>Add</td>
<td>Search (tuberculosis OR TB OR poliomyelitis OR polio OR rotavirus OR diphtheria OR tetanus OR pertussis OR pneumococcal OR pneumonia OR measles OR &quot;yellow fever&quot; OR &quot;Hepatitis B&quot; OR &quot;Haemophilus influenzae&quot; OR &quot;Hemophilus influenzae&quot;)</td>
<td>Sort by: Best Match</td>
</tr>
<tr>
<td>45</td>
<td>Add</td>
<td>Search (incidence OR prevalence OR mortality)</td>
<td>Sort by: Best Match</td>
</tr>
<tr>
<td>43</td>
<td>Add</td>
<td>Search (&quot;HIV infected&quot; OR &quot;HIV exposed&quot; OR &quot;HIV-infected&quot; OR &quot;HIV-exposed&quot; OR &quot;HIV positive&quot; OR &quot;HIV exposed uninfected&quot;)</td>
<td>Sort by: Best Match</td>
</tr>
<tr>
<td>41</td>
<td>Add</td>
<td>Search (Angola OR Benin OR Botswana OR &quot;Burkina Faso&quot; OR Burundi OR Cameroon OR &quot;Cape Verde&quot; OR &quot;Central African Republic&quot; OR Chad OR Congo OR &quot;Democratic Republic of Congo&quot; OR DRC OR Djibouti OR &quot;Equatorial Guinea&quot; OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR &quot;Guinea Bissau&quot; OR Guinea OR &quot;Ivory Coast&quot; OR &quot;Cote d'Ivoire&quot; OR Kenya OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR &quot;Republic of the Congo&quot; OR Reunion OR Rwanda OR Senegal OR Seychelles OR &quot;Sierra Leone&quot; OR &quot;Sao Tome and Principe&quot; OR Somalia OR &quot;South Africa&quot; OR &quot;South Sudan&quot; OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR Zambia OR &quot;Sub-Saharan Africa&quot;)</td>
<td>Sort by: Best Match</td>
</tr>
</tbody>
</table>
Figure 1: Flow diagram of the selection process
Figure 2: Forest plot of studies with data on incidence rates of tuberculosis in HIV-exposed children
<table>
<thead>
<tr>
<th>Study Year</th>
<th>Country</th>
<th>ES (95% CI)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuogi 2013</td>
<td>Kenya</td>
<td>0.07 (0.06, 0.10)</td>
<td>5.40</td>
</tr>
<tr>
<td>Adams 2014</td>
<td>Tanzania</td>
<td>0.05 (0.04, 0.06)</td>
<td>5.44</td>
</tr>
<tr>
<td>Anigilaje 2016</td>
<td>Nigeria</td>
<td>0.20 (0.16, 0.24)</td>
<td>5.16</td>
</tr>
<tr>
<td>Auld 2014</td>
<td>Cote d’Ivoire</td>
<td>0.07 (0.06, 0.08)</td>
<td>5.45</td>
</tr>
<tr>
<td>Bonnet 2018</td>
<td>Uganda</td>
<td>0.06 (0.03, 0.12)</td>
<td>5.10</td>
</tr>
<tr>
<td>Buck 2013</td>
<td>Malawi</td>
<td>0.32 (0.31, 0.33)</td>
<td>5.44</td>
</tr>
<tr>
<td>Cruz 2015</td>
<td>Botswana</td>
<td>0.01 (0.00, 0.05)</td>
<td>5.40</td>
</tr>
<tr>
<td>De Maayar 2011</td>
<td>South Africa</td>
<td>0.09 (0.03, 0.19)</td>
<td>4.58</td>
</tr>
<tr>
<td>Ebonyi 2016b</td>
<td>Nigeria</td>
<td>0.33 (0.30, 0.36)</td>
<td>5.28</td>
</tr>
<tr>
<td>Kasambira 2011</td>
<td>South Africa</td>
<td>0.29 (0.24, 0.35)</td>
<td>4.93</td>
</tr>
<tr>
<td>Obiagwu 2013</td>
<td>Nigeria</td>
<td>0.18 (0.05, 0.40)</td>
<td>2.78</td>
</tr>
<tr>
<td>Okechukwu 2011</td>
<td>Nigeria</td>
<td>0.20 (0.14, 0.26)</td>
<td>4.95</td>
</tr>
<tr>
<td>Rose 2012</td>
<td>Tanzania</td>
<td>0.11 (0.04, 0.23)</td>
<td>4.34</td>
</tr>
<tr>
<td>Westerlund 2014</td>
<td>Ethiopia</td>
<td>0.14 (0.09, 0.21)</td>
<td>4.85</td>
</tr>
<tr>
<td>Subtotal</td>
<td></td>
<td>0.15 (0.08, 0.22)</td>
<td>69.10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(I^2 = 99.13%, p = 0.00)</td>
<td></td>
</tr>
<tr>
<td>2000-2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brailitstein 2009</td>
<td>Kenya</td>
<td>0.04 (0.03, 0.04)</td>
<td>5.47</td>
</tr>
<tr>
<td>Ferrand 2010</td>
<td>Zimbabwe</td>
<td>0.17 (0.11, 0.25)</td>
<td>4.77</td>
</tr>
<tr>
<td>Hesseling 2006</td>
<td>South Africa</td>
<td>0.16 (0.09, 0.24)</td>
<td>4.66</td>
</tr>
<tr>
<td>Hesseling 2009b</td>
<td>South Africa</td>
<td>0.02 (0.01, 0.02)</td>
<td>5.47</td>
</tr>
<tr>
<td>Robinson 2007</td>
<td>South Africa</td>
<td>0.57 (0.42, 0.72)</td>
<td>3.14</td>
</tr>
<tr>
<td>Subtotal</td>
<td></td>
<td>0.08 (0.05, 0.11)</td>
<td>23.51</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(I^2 = 96.98%, p = 0.00)</td>
<td></td>
</tr>
<tr>
<td>1991-2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeena 2000</td>
<td>South Africa</td>
<td>0.41 (0.22, 0.61)</td>
<td>2.40</td>
</tr>
<tr>
<td>Meyers 2000</td>
<td>South Africa</td>
<td>0.11 (0.06, 0.17)</td>
<td>4.99</td>
</tr>
<tr>
<td>Subtotal</td>
<td></td>
<td>0.13 (0.08, 0.18)</td>
<td>7.39</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(I^2 = .%, p = .)</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity between groups: p = 0.079
Overall (I^2 = 99.21%, p = 0.00);

0.16 (0.12, 0.19) 100.00

Figure 3: Forest plot of studies with data on the prevalence of tuberculosis in HIV-infected children
Figure 4: Forest plot of studies with data on the prevalence of hepatitis B virus infection in HIV-infected and HIV-exposed children.
Figure 5: Trends in the incidence of tuberculosis in HIV-infected and exposed children with respect to publication years
Figure 6: Trends in the prevalence of hepatitis B virus infection in HIV-infected and exposed children with respect to publication years.
Figure 7: Funnel plot of studies reporting on the prevalence of tuberculosis in HIV-infected children.
Figure 8: Funnel plot of studies reporting on the prevalence of hepatitis B virus infection in HIV-infected children.
Figure 9: Funnel plot of studies reporting on the case-fatality rate of tuberculosis in HIV-infected children
Table 1: Characteristics of the study population

<table>
<thead>
<tr>
<th>First author and year</th>
<th>Study period</th>
<th>Study design</th>
<th>Country</th>
<th>Sample size</th>
<th>VPD</th>
<th>Outcomes</th>
<th>HIV status</th>
<th>Quality scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abuogi 2013&lt;sup&gt;15&lt;/sup&gt;</td>
<td>2009 - 2010</td>
<td>Cohort</td>
<td>Kenya</td>
<td>689</td>
<td>Tuberculosis</td>
<td>C, I, P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Adams 2014&lt;sup&gt;16&lt;/sup&gt;</td>
<td>2006 - 2012</td>
<td>Cross-sectional</td>
<td>Tanzania</td>
<td>1193</td>
<td>Tuberculosis</td>
<td>C, P</td>
<td>HI</td>
<td>4</td>
</tr>
<tr>
<td>Alemu 2016&lt;sup&gt;17&lt;/sup&gt;</td>
<td>2009 - 2014</td>
<td>Cohort</td>
<td>Ethiopia</td>
<td>645</td>
<td>Tuberculosis</td>
<td>I</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Anigilaje 2016&lt;sup&gt;18&lt;/sup&gt;</td>
<td>2010 - 2013</td>
<td>Cohort</td>
<td>Nigeria</td>
<td>368</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Auld 2014&lt;sup&gt;19&lt;/sup&gt;</td>
<td>2004 - 2008</td>
<td>Cohort</td>
<td>Cote d'Ivoire</td>
<td>2110</td>
<td>Tuberculosis</td>
<td>I, P</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Bakeera 2011&lt;sup&gt;20&lt;/sup&gt;</td>
<td>2003 - 2006</td>
<td>Cohort</td>
<td>Uganda</td>
<td>1806</td>
<td>Tuberculosis</td>
<td>I, C</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Bonnet 2018&lt;sup&gt;21&lt;/sup&gt;</td>
<td>2012 - 2014</td>
<td>Cohort</td>
<td>Uganda</td>
<td>113</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Braithstein 2009&lt;sup&gt;22&lt;/sup&gt;</td>
<td>2001 - 2007</td>
<td>Cohort</td>
<td>Kenya</td>
<td>6,535</td>
<td>Tuberculosis</td>
<td>I, P</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Buck 2013&lt;sup&gt;23&lt;/sup&gt;</td>
<td>2010</td>
<td>Cohort</td>
<td>Malawi</td>
<td>4874</td>
<td>Tuberculosis</td>
<td>C, P</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Carlucci 2017&lt;sup&gt;24&lt;/sup&gt;</td>
<td>2012 - 2014</td>
<td>Cohort</td>
<td>Multiple</td>
<td>386</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Cavanaugh 2012&lt;sup&gt;25&lt;/sup&gt;</td>
<td>2006 - 2007</td>
<td>Cross-sectional</td>
<td>Kenya</td>
<td>323</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Chaya 2016&lt;sup&gt;26&lt;/sup&gt;</td>
<td>2006 - 2011</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>47</td>
<td>Tuberculosis</td>
<td>I</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Cruz 2015&lt;sup&gt;27&lt;/sup&gt;</td>
<td>NR</td>
<td>Cohort</td>
<td>Botswana</td>
<td>100</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Dangor 2013&lt;sup&gt;28&lt;/sup&gt;</td>
<td>2005 - 2009</td>
<td>Time-series analysis</td>
<td>South Africa</td>
<td>1985</td>
<td>Tuberculosis</td>
<td>I</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>De Maayar 2011&lt;sup&gt;29&lt;/sup&gt;</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>58</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Ebonyi 2016&lt;sup&gt;30&lt;/sup&gt;</td>
<td>2005 - 2013</td>
<td>Cohort</td>
<td>Nigeria</td>
<td>260</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Ebonyi 2016b&lt;sup&gt;31&lt;/sup&gt;</td>
<td>2005-2012</td>
<td>Cohort</td>
<td>Nigeria</td>
<td>876</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Elenga 2005&lt;sup&gt;32&lt;/sup&gt;</td>
<td>2000-2003</td>
<td>Cohort</td>
<td>Cote d'Ivoire</td>
<td>282</td>
<td>Tuberculosis</td>
<td>I</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Ferrand 2010&lt;sup&gt;33&lt;/sup&gt;</td>
<td>2007-2008</td>
<td>Cross-sectional</td>
<td>Zimbabwe</td>
<td>139</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Hall 2017&lt;sup&gt;34&lt;/sup&gt;</td>
<td>2005-2008</td>
<td>Cohort</td>
<td>South Africa</td>
<td>224</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Hesseling 2009a&lt;sup&gt;35&lt;/sup&gt;</td>
<td>2004-2006</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>3321</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Hesseling 2005&lt;sup&gt;36&lt;/sup&gt;</td>
<td>1992-2000</td>
<td>Cohort</td>
<td>South Africa</td>
<td>93</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>8</td>
</tr>
<tr>
<td>Hesseling 2006&lt;sup&gt;37&lt;/sup&gt;</td>
<td>2002-2005</td>
<td>Cohort</td>
<td>South Africa</td>
<td>108</td>
<td>Tuberculosis</td>
<td>C, P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Hesseling 2009b&lt;sup&gt;38&lt;/sup&gt;</td>
<td>2004-2006</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>3321</td>
<td>Tuberculosis</td>
<td>I, P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Hicks 2014&lt;sup&gt;39&lt;/sup&gt;</td>
<td>2009-2010</td>
<td>Cohort</td>
<td>South Africa</td>
<td>64</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Jeena 2000&lt;sup&gt;40&lt;/sup&gt;</td>
<td>1995-1998</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>27</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Kasambira 2011&lt;sup&gt;41&lt;/sup&gt;</td>
<td>2006-2009</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>270</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Madhi 2000b&lt;sup&gt;42&lt;/sup&gt;</td>
<td>1996-1997</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>67</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Meyers 2000&lt;sup&gt;43&lt;/sup&gt;</td>
<td>1996</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>144</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Study Design</td>
<td>Country</td>
<td>Sample Size</td>
<td>Disease</td>
<td>Control</td>
<td>Study Type</td>
<td>Region</td>
</tr>
<tr>
<td>------------------</td>
<td>----------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------</td>
<td>------------------------</td>
<td>----------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>Mwangwa 2017</td>
<td>2012-2013</td>
<td>Cohort</td>
<td>Multiple</td>
<td>17</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Obiagwu 2013</td>
<td>2010</td>
<td>Cross-sectional</td>
<td>Nigeria</td>
<td>22</td>
<td>Tuberculosis, Measles</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Osman 2017</td>
<td>2005-2012</td>
<td>Cohort</td>
<td>South Africa</td>
<td>3143</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Padayatchi 2006</td>
<td>1993-2002</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>6</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Palme 2002</td>
<td>1995-1997</td>
<td>Cohort</td>
<td>Ethiopia</td>
<td>58</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Patel 2013</td>
<td>2007-2009</td>
<td>Cohort</td>
<td>Congo DRC</td>
<td>31</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Robinson 2007</td>
<td>1999-2001</td>
<td>Case-control</td>
<td>South Africa</td>
<td>47</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Rose 2012</td>
<td>2008-2010</td>
<td>Cohort</td>
<td>Tanzania</td>
<td>54</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Schaaf 2007</td>
<td>2003-2005</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>133</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Soeters 2005</td>
<td>2000-2001</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>43</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>4</td>
</tr>
<tr>
<td>Walters 2014</td>
<td>2003-2010</td>
<td>Cohort</td>
<td>South Africa</td>
<td>494</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Walters 2008</td>
<td>2003-2005</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>137</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Westerlund 2014</td>
<td>2003-2008</td>
<td>Cohort</td>
<td>Ethiopia</td>
<td>138</td>
<td>Tuberculosis</td>
<td>P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Wiseman 2011</td>
<td>2004-2006</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>52</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Yotebieng 2010</td>
<td>2004-2008</td>
<td>Cohort</td>
<td>South Africa</td>
<td>573</td>
<td>Tuberculosis</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Kouakoussou 2004</td>
<td>2003</td>
<td>Cohort</td>
<td>Cote d’Ivoire</td>
<td>270</td>
<td>Tuberculosis</td>
<td>I</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Abra 2014</td>
<td>2014</td>
<td>Cross-sectional</td>
<td>Ethiopia</td>
<td>253</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Ashir 2009</td>
<td>2007</td>
<td>Case-control</td>
<td>Nigeria</td>
<td>284</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Beghin 2017</td>
<td>2014</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>183</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Chotun 2015</td>
<td>2011-2012</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>1000</td>
<td>HBV infection</td>
<td>P, HE</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Uleanya 2016</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Nigeria</td>
<td>140</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>4</td>
</tr>
<tr>
<td>Dziuban 2013</td>
<td>2009-2011</td>
<td>Cross-sectional</td>
<td>Swaziland</td>
<td>500</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>3</td>
</tr>
<tr>
<td>Ikpe 2013</td>
<td>2010-2011</td>
<td>Cross-sectional</td>
<td>Nigeria</td>
<td>166</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>4</td>
</tr>
<tr>
<td>Jooste 2016</td>
<td>2015-2016</td>
<td>Cohort</td>
<td>South Africa</td>
<td>625</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Muro 2013</td>
<td>2006-2008</td>
<td>Cross-sectional</td>
<td>Tanzania</td>
<td>157</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Mutwa 2013</td>
<td>2010</td>
<td>Cohort</td>
<td>Rwanda</td>
<td>88</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Nwolisa 2013</td>
<td>2010</td>
<td>Cross-sectional</td>
<td>Nigeria</td>
<td>139</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>4</td>
</tr>
<tr>
<td>Sadoh 2011</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Nigeria</td>
<td>155</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Telatela 2007</td>
<td>2006</td>
<td>Cross-sectional</td>
<td>Tanzania</td>
<td>167</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>4</td>
</tr>
<tr>
<td>Varo 2016</td>
<td>2008-2010</td>
<td>Cross-sectional</td>
<td>Malawi</td>
<td>91</td>
<td>HBV infection</td>
<td>P</td>
<td>HI</td>
<td>3</td>
</tr>
<tr>
<td>Study</td>
<td>Year(s)</td>
<td>Study Design</td>
<td>Country</td>
<td>Sample Size</td>
<td>Condition</td>
<td>Infections</td>
<td>VPD</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>--------------</td>
<td>---------</td>
<td>-------------</td>
<td>-----------</td>
<td>------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>Wirth 2015&lt;sup&gt;76&lt;/sup&gt;</td>
<td>2009-2010</td>
<td>Case-control</td>
<td>Botswana</td>
<td>189</td>
<td>Measles</td>
<td>C</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>du Plessis 2018&lt;sup&gt;14&lt;/sup&gt;</td>
<td>2013 - 2015</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>300</td>
<td>Pertussis</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Gill 2016&lt;sup&gt;77&lt;/sup&gt;</td>
<td>2015</td>
<td>Cohort</td>
<td>Zambia</td>
<td>347</td>
<td>Pertussis</td>
<td>I</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Soofie 2016&lt;sup&gt;78&lt;/sup&gt;</td>
<td>2015</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>599</td>
<td>Pertussis</td>
<td>C, I, P</td>
<td>HE</td>
<td>5</td>
</tr>
<tr>
<td>Johnson 2000&lt;sup&gt;79&lt;/sup&gt;</td>
<td>1996-1997</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>31</td>
<td>Rotavirus gastroenteritis</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Moyo 2014&lt;sup&gt;80&lt;/sup&gt;</td>
<td>2010-2011</td>
<td>Case-control</td>
<td>Tanzania</td>
<td>26</td>
<td>Rotavirus gastroenteritis</td>
<td>P</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Asbjörnsdóttir 2013&lt;sup&gt;81&lt;/sup&gt;</td>
<td>1999-2002</td>
<td>Cohort</td>
<td>Kenya</td>
<td>388</td>
<td>Pneumococcal infection</td>
<td>C, I</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Nathoo 1996&lt;sup&gt;82&lt;/sup&gt;</td>
<td>1993-1994</td>
<td>Cohort</td>
<td>Zimbabwe</td>
<td>168</td>
<td>Pneumococcal infection</td>
<td>P</td>
<td>HI</td>
<td>7</td>
</tr>
<tr>
<td>Zar 2001&lt;sup&gt;83&lt;/sup&gt;</td>
<td>1998</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>151</td>
<td>Pneumococcal infection</td>
<td>P</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Jones 1998&lt;sup&gt;84&lt;/sup&gt;</td>
<td>1996</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>25</td>
<td>Pneumococcal infection</td>
<td>C</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Roca 2010&lt;sup&gt;85&lt;/sup&gt;</td>
<td>2004-2006</td>
<td>Cross-sectional</td>
<td>Mozambique</td>
<td>54</td>
<td>Pneumococcal infection</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>Cohen 2016&lt;sup&gt;86&lt;/sup&gt;</td>
<td>2009 - 2013</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>211</td>
<td>Pneumococcal infection</td>
<td>I</td>
<td>HEU, HI</td>
<td>4</td>
</tr>
<tr>
<td>Nunes 2011&lt;sup&gt;87&lt;/sup&gt;</td>
<td>2003-2008</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>938</td>
<td>Pneumococcal infection</td>
<td>I</td>
<td>HI</td>
<td>6</td>
</tr>
<tr>
<td>von Mollendorf 2017a&lt;sup&gt;88&lt;/sup&gt;</td>
<td>2009–2013</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>495</td>
<td>Pneumococcal infection</td>
<td>C, I</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>von Gottberg 2013&lt;sup&gt;89&lt;/sup&gt;</td>
<td>2003-2008</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>1749</td>
<td>Pneumococcal infection</td>
<td>I</td>
<td>HI</td>
<td>5</td>
</tr>
<tr>
<td>Nyasulu 2011&lt;sup&gt;90&lt;/sup&gt;</td>
<td>2003-2005</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>1124</td>
<td>Pneumococcal infection</td>
<td>C</td>
<td>HI</td>
<td>6</td>
</tr>
</tbody>
</table>

NR - Not recorded; C - Case-fatality rate; I – Incidence; P – Prevalence; Hib- Haemophilus influenzae type b; HI- HIV-infected; HE- HIV-exposed; HEU – HIV-exposed uninfected; VPD - vaccine-preventable diseases.
## Appendix

### Search strategy - PubMed

<table>
<thead>
<tr>
<th>Search</th>
<th>Add to builder</th>
<th>Query</th>
<th>Items found</th>
</tr>
</thead>
<tbody>
<tr>
<td>#6</td>
<td>Add</td>
<td>Search (((#1) AND #2) AND #3) AND #4) AND #5 Sort by: Best Match</td>
<td>1364</td>
</tr>
<tr>
<td>#4</td>
<td>Add</td>
<td>Search (newborn* OR bab* OR infan* OR child* OR adolescen* OR teen*) Sort by: Best Match</td>
<td>3843580</td>
</tr>
<tr>
<td>#2</td>
<td>Add</td>
<td>Search (tuberculosis OR TB OR poliomyelitis OR polio OR rotavirus OR diphtheria OR tetanus OR pertussis OR pneumococcal OR pneumonia OR measles OR &quot;yellow fever&quot; OR &quot;Hepatitis B&quot; OR &quot;Haemophilus influenza&quot; OR &quot;Hemophilus influenza&quot; OR influenza) Sort by: Best Match</td>
<td>707401</td>
</tr>
<tr>
<td>#5</td>
<td>Add</td>
<td>Search (incidence OR prevalence OR mortality) Sort by: Best Match</td>
<td>3171459</td>
</tr>
<tr>
<td>#3</td>
<td>Add</td>
<td>Search (&quot;HIV infected&quot; OR &quot;HIV exposed&quot; OR &quot;HIV-infected&quot; OR &quot;HIV-exposed&quot; OR &quot;HIV positive&quot; OR &quot;HIV exposed uninfected&quot;) Sort by: Best Match</td>
<td>74539</td>
</tr>
<tr>
<td>#1</td>
<td>Add</td>
<td>Search (Angola OR Benin OR Botswana OR &quot;Burkina Faso&quot; OR Burundi OR Cameroon OR &quot;Cape Verde&quot; OR &quot;Central African Republic&quot; OR Chad OR Congo OR &quot;Democratic Republic of Congo&quot; OR DRC OR Djibouti OR &quot;Equatorial Guinea&quot; OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR &quot;Guinea Bissau&quot; OR Guinea OR &quot;Ivory Coast&quot; OR &quot;Cote d'Ivoire&quot; OR Kenya OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR &quot;Republic of the Congo&quot; OR Reunion OR Rwanda OR Senegal OR Seychelles OR &quot;Sierra Leone&quot; OR &quot;Sao Tome and Principe&quot; OR Somalia OR &quot;South Africa&quot; OR &quot;South Sudan&quot; OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR Zambia OR Zimbabwe OR Africa OR &quot;sub Saharan Africa&quot;) Sort by: Best Match</td>
<td>558013</td>
</tr>
</tbody>
</table>